Mexico Molecular Diagnostics Market (2025-2030)
The Mexico Molecular Diagnostics Market was valued at $118.2 Million in 2025 and projected to reach to $178.5 Million by 2030, representing a compound annual growth rate of 8.6%. Mexico's molecular diagnostics market is positioned for sustained growth through 2030, supported by expanding healthcare access and rising demand for precision medicine solutions.
Mexico Molecular Diagnostics Market Trends and Insights
- This growth trajectory reflects Mexico's increasing healthcare infrastructure investments and rising demand for precision diagnostic solutions across infectious disease, oncology, and genetic testing segments.
- Mexico's market expansion is driven by improving laboratory capabilities, growing patient awareness, and enhanced access to advanced diagnostic technologies in both urban and emerging healthcare centers. The 8.6% compound annual growth rate positions Mexico as a significant contributor to the Latin American molecular diagnostics landscape.
- Mexico's healthcare sector is increasingly adopting molecular testing for infectious disease surveillance, particularly following pandemic-related investments in diagnostic capacity.
- By 2030, Mexico's market is expected to benefit from continued healthcare modernization, expanded insurance coverage, and the integration of molecular diagnostics into routine clinical practice across public and private healthcare systems..
Key Market Statistics
- CAGR (2025-2030) 8.6% CAGR
- Market Size, 2025 ~USD 118.2 Million
- Forecast, 2030 ~USD 178.5 Million
- Country Mexico
Mexico Molecular Diagnostics Market Overview
Market Valuation Growth :
Mexico's molecular diagnostics market is valued at $118.2 million in 2025, with a projected CAGR of 8.6% through 2030, reaching $178.5 million. This represents a 50.9% increase over the five-year forecast period, demonstrating robust market expansion.
Healthcare Infrastructure Investment :
Mexico is experiencing significant investments in healthcare infrastructure modernization, particularly in diagnostic capabilities. Government initiatives and private sector expansion are driving adoption of advanced molecular diagnostic technologies across urban and emerging healthcare facilities.
Key Application Segments :
The Mexican market shows strong demand across infectious disease diagnostics, oncology testing, and genetic screening. COVID-19 pandemic legacy, rising cancer prevalence, and increasing genetic disorder awareness are primary drivers for molecular diagnostic adoption in these segments.
Regional Market Dynamics :
Mexico's molecular diagnostics market growth outpaces several Latin American peers, driven by population size, rising middle-class healthcare spending, and increasing prevalence of chronic diseases. Strategic partnerships between local healthcare providers and international diagnostic companies are accelerating market penetration.
Mexico Molecular Diagnostics Market Dynamics
- The country's growing middle class and increasing healthcare expenditure are creating favorable conditions for diagnostic technology adoption.
- Key drivers include rising infectious disease burden, growing cancer incidence, and enhanced genetic testing awareness among Mexican healthcare providers and patients. The market will benefit from continued healthcare infrastructure investments and regulatory improvements facilitating diagnostic innovation.
- Strategic collaborations between international diagnostic manufacturers and Mexican healthcare institutions are expected to accelerate market development.
- Additionally, telemedicine integration and point-of-care molecular testing expansion will drive accessibility in both metropolitan and underserved regions, supporting the projected 8.6% CAGR through 2030..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Stryker Corporation
- Abbott Laboratories
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- Mexico's molecular diagnostics market is valued at $118.2 million in 2025 and is forecast to grow to $178.5 million by 2030, representing an 8.6% CAGR.
- Mexico's market growth is driven by healthcare infrastructure modernization, increased diagnostic adoption, and expanded access to precision medicine technologies.
- Mexico's infectious disease and oncology segments are primary growth drivers, supported by enhanced laboratory capabilities and clinical integration.
- Mexico's private healthcare sector and government health initiatives are accelerating molecular diagnostics adoption across the country.
Molecular Diagnostics Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | HEPATITIS (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 9.6% from 2025 to 2030 |
| Largest Segment | LAB TESTS (Test Type) |
| Market Size Base Year (Billions) | ~USD 19.44 (2025) |
| Revenue Forecast (Billions) | ~USD 30.74 (2030) |
| Segments Covered | Product & Service, Test Type, Sample Type, Type |
Mexico Molecular Diagnostics Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product & Service
- Instruments
- Reagents & Kits
- Services & Software
By Test Type
- Lab Tests
- Poc Tests
By Sample Type
- Blood, Serum & Plasma
- Other Sample Types
- Urine
By Type
- Breast Cancer
- Colorectal Cancer
- Influenza
- Lung Cancer
- Other Cancers
- Other Respiratory Infectious Diseases
- Pharyngitis
- Prostate Cancer
- Tuberculosis
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers of molecular diagnostic platforms and instruments need Mexico-specific market data to assess market opportunity, identify distribution partnerships, and develop localized product strategies for the growing Mexican healthcare sector.
- In Vitro Diagnostics (IVD) Companies : IVD companies require detailed insights into Mexico's molecular diagnostics demand, reimbursement policies, and competitive landscape to optimize product portfolios, pricing strategies, and market penetration approaches in this expanding Latin American market.
- Healthcare Facility Operators : Hospital networks, diagnostic laboratories, and healthcare providers in Mexico need market intelligence to justify capital investments in molecular diagnostic capabilities, benchmark against peers, and plan service expansion aligned with market growth trends.
- Investment & Private Equity Firms : Investors evaluating opportunities in Mexican healthcare diagnostics require comprehensive market sizing, growth projections, and competitive analysis to assess investment returns, identify acquisition targets, and evaluate portfolio company performance.
- Healthcare Consultants & Advisors : Management consultants and healthcare advisors serving clients in Mexico need country-specific market data to support strategic recommendations, feasibility studies, and business case development for diagnostic service expansion and technology adoption initiatives.
Key Companies in the Mexico Molecular Diagnostics Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CEPHEID INC. | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease and HAIs),Virology, oncology, and genetics assays, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, logistics, O&M, mission-critical facilities), |
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CODEXIS, INC. | United States | Public Company | CodeEvolver-enabled enzyme products and services,ECO Synthesis RNAi manufacturing platform (licenses, milestones, royalties),Other technology partnerships and R&D collaborations, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging,Pathology and centres of excellence, |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media (clinical),Urinalysis test strips, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array instruments and consumables, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, treatment support),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa ProVu, CoolSeal), |
| BIOMÉRIEUX | France | Public Company | |
| ABBOTT LABORATORIES | United States | Public Company | Medical Devices (cardiovascular, diabetes care, neuromodulation),Diagnostic Products (lab, molecular, point-of-care, rapid),Nutritional Products (pediatric, adult, infant formula), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant/viral load assays),Oncology and sexual and reproductive health assays, |
| REVVITY, INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, autoimmune),Life science reagents and assay platforms,Instruments, software, and services, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
CEPHEID INC.
Cepheid Inc. is a private U.S. diagnostic company founded in 1996 with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing solutions.
FLUOR CORPORATION
Fluor Corporation is a large U.S. engineering and construction company founded in 1912, operating as a public company with approximately 23,000 employees. The firm provides design, engineering, procurement, and construction services across multiple industries.
SANOFI
Sanofi is a major French pharmaceutical company founded in 1994 and publicly traded, with over 74,800 employees worldwide. The company develops and manufactures prescription medicines, vaccines, and consumer healthcare products.
CODEXIS, INC.
Codexis, Inc. is a publicly traded U.S. biotechnology company founded in 2002 with 146 employees. The company develops and commercializes biocatalysts and enzymes for pharmaceutical and chemical manufacturing.
UNILABS
Unilabs is a private Swiss clinical laboratory and diagnostics company founded in 1987 with 1,897 employees. The company offers laboratory testing and diagnostic services across Europe.
EIKEN CHEMICAL CO., LTD.
Eiken Chemical Co., Ltd. is a publicly traded Japanese chemical and diagnostics company founded in 1939 with 696 employees. The company manufactures diagnostic reagents, pharmaceuticals, and chemical products.
DANAHER CORPORATION
Danaher Corporation is a large publicly traded U.S. conglomerate founded in 1969 with 59,000 employees. The company operates across multiple sectors including diagnostics, life sciences, and environmental solutions.
ILLUMINA, INC.
Illumina, Inc. is a publicly traded U.S. genomics company founded in 1998 with 8,625 employees. The company designs and manufactures DNA sequencing and array-based analysis systems.
HOLOGIC, INC.
Hologic, Inc. is a private U.S. medical device company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and surgical products focused on women's health and oncology.
BIOMÉRIEUX
bioMérieux is a publicly traded French diagnostics company founded in 1963 with 14,894 employees. The company specializes in in vitro diagnostics for infectious diseases, industrial microbiology, and food safety.
ABBOTT LABORATORIES
Abbott Laboratories is a large publicly traded U.S. healthcare company founded in 1888 with 115,000 employees. The company manufactures pharmaceuticals, diagnostics, medical devices, and nutritional products.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a major publicly traded U.S. life sciences company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, software, and services for research and diagnostics.
QIAGEN N.V.
QIAGEN N.V. is a publicly traded Dutch life sciences company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics, sample preparation, and bioinformatics solutions.
REVVITY, INC.
Revvity, Inc. is a publicly traded U.S. life sciences and diagnostics company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for research and diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a publicly traded Spanish pharmaceutical and diagnostics company founded in 1909 with 25,000 employees. The company specializes in plasma-derived medicines, transfusion medicine, and diagnostics.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise valuation data for Mexico's molecular diagnostics market ($118.2M in 2025) with verified 8.6% CAGR projections through 2030. Essential for investment decisions, market entry strategies, and competitive positioning in the Mexican healthcare sector.
- Segment-Specific Insights : Access detailed analysis of Mexico's key molecular diagnostics segments including infectious disease, oncology, and genetic testing. Understand segment-specific growth drivers, adoption rates, and revenue forecasts to identify highest-opportunity therapeutic areas for expansion.
- Competitive Landscape Intelligence : Gain comprehensive understanding of Mexico's molecular diagnostics competitive environment, including key players, market share distribution, and strategic partnerships. Critical for benchmarking performance and identifying collaboration or acquisition opportunities in the Mexican market.
- Healthcare Infrastructure & Regulatory Context : Understand Mexico's healthcare infrastructure investments, regulatory framework, and reimbursement landscape specific to molecular diagnostics. Essential for navigating market entry, pricing strategies, and compliance requirements for diagnostic products and services.
- Strategic Growth Planning : Leverage Mexico-specific market data to develop targeted growth strategies, resource allocation plans, and go-to-market approaches. Support board presentations, investor communications, and long-term business planning with country-specific market intelligence and forecasts.
Frequently asked questions
What is the current size of Mexico's molecular diagnostics market?
Mexico's molecular diagnostics market is valued at $118.2 million in 2025 and is projected to reach $178.5 million by 2030.
What is the expected growth rate for Mexico's molecular diagnostics market?
Mexico's molecular diagnostics market is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.
Which segments are driving growth in Mexico's molecular diagnostics market?
Mexico's infectious disease testing, oncology diagnostics, and genetic testing segments are primary growth drivers, supported by improved laboratory infrastructure and clinical adoption.
What factors are contributing to market expansion in Mexico?
Mexico's market expansion is driven by healthcare modernization, increased diagnostic awareness, government health initiatives, and growing private sector investment in precision medicine.
How does Mexico's market compare to the broader Latin American region?
Mexico's 8.6% CAGR positions it as a significant contributor to Latin America's molecular diagnostics growth, with strong infrastructure and healthcare sector development supporting market expansion.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global molecular diagnostics market. Exhaustive secondary research was done to collect information on the molecular diagnostics market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the molecular diagnostics market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Breakdown Of Primary Participants
Note 1: Others include Sales Managers, Marketing Managers, and Product Managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers:
Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate and validate the molecular diagnostics market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.
- The key players in the industry have been identified through extensive secondary research.
- Primary and secondary research have determined the revenues generated by leading players operating in the molecular diagnostics market.
- All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global molecular diagnostics market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze the micromarkets concerning individual growth trends, prospects, and contributions to the overall molecular diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market with respect to five regions, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the molecular diagnostics market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the molecular diagnostics market, along with the macroeconomic outlook for each region
Get the Full Molecular Diagnostics Market Report
Full forecast, segment splits, and company analysis for all Molecular Diagnostics Market.
- Canada Molecular Diagnostics Market
- US Molecular Diagnostics Market
- Germany Molecular Diagnostics Market
- UK Molecular Diagnostics Market
- France Molecular Diagnostics Market
- Italy Molecular Diagnostics Market
- Spain Molecular Diagnostics Market
- Russia Molecular Diagnostics Market
- Switzerland Molecular Diagnostics Market
- China Molecular Diagnostics Market
- Japan Molecular Diagnostics Market
- India Molecular Diagnostics Market
- Australia Molecular Diagnostics Market
- South Korea Molecular Diagnostics Market
- Brazil Molecular Diagnostics Market
- Saudi Arabia Molecular Diagnostics Market
- UAE Molecular Diagnostics Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report